News | February 25, 2023
EMA recommends refusal of the marketing authorization for Lagevrio
Merck and Ridgeback will appeal the decision and request a re-examination of the CHMP’s opinion.
Merck and Ridgeback will appeal the decision and request a re-examination of the CHMP’s opinion.
This sBLA submission is supported by clinical, pre-clinical, and manufacturing data demonstrating the safety, tolerability, and immunogenicity of the bivalent vaccine.
Submissions based on favorable MagnetisMM-3 trial results in patients with relapsed or refractory multiple myeloma
Projected ~US$100 million cash balance of combined company expected to fund operations through mid-2025 and to clinical data over the next 12 to 24 months
More than 5 lakh patients availed the benefit of queue-less OPD registration using this service
The marketing authorisations for three generic drugs signifying advances in cancer treatment will considerably benefit thousands of patients by improving access, ensuring affordability
Ayurveda is one of the most advanced sciences of its times
The new Beyfortus data are consistent with all data accumulated to date and confirm its strong profile
This artificial RNA ligase has higher thermostability than natural RNA ligase
This action follows the recent acceptance of the Marketing Authorization Application (MAA) for Pfizer’s RSV vaccine candidate by the European Medicines Agency
Subscribe To Our Newsletter & Stay Updated
